Madrigal Pharmaceuticals IncChange company Symbol lookupSelect an option...MDGL Madrigal Pharmaceuticals IncITCL Banco Itau ChileTOPS Top Ships IncBOLT Bolt Biotherapeutics IncACET Adicet Bio IncVCNX Vaccinex IncDYNT Dynatronics CorpALDX Aldeyra Therapeutics IncRVLP RVL Pharmaceuticals PLCMINDP Mind Technology IncGo
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| August 8, 2023 | Q2 2023 Earnings Release | -$4.69 | -$5.08 to -$4.22 | -$4.14 |
| May 9, 2023 | Q1 2023 Earnings Release | -$4.23 | -$5.73 to -$4.26 | -$3.36 |
| February 23, 2023 | Q4 2022 Earnings Release | -$4.98 | -$5.13 to -$3.47 | -$3.78 |
| November 3, 2022 | Q3 2022 Earnings Release | -$4.75 | -$4.60 to -$3.50 | -$3.79 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.